# Pcv21 vaccine PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/pcv21-vaccine

> The next catalyst for pcv21 vaccine, sponsored by Sanofi (SNY), is its topline data readout, May to Aug 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | pcv21 vaccine |
| Codes | PCV21 |
| Sponsor | Sanofi (SNY) https://sec-api.dev/companies/sny/catalysts |
| Indications | [Pneumococcal Immunization](https://sec-api.dev/indications/pneumococcal-immunization) |
| Modality |  |
| FDA designations | none disclosed |

## Timeline

### May to Aug 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Pneumococcal Immunization.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06736041 (Study of a 4-Dose Regimen of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-05-17 (ESTIMATED); Lead Sponsor Sanofi Pasteur, a Sanofi Company." https://clinicaltrials.gov/study/NCT06736041

### May 2027: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Pneumococcal Immunization.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06736041 (Study of a 4-Dose Regimen of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-05-17 (ESTIMATED); Lead Sponsor Sanofi Pasteur, a Sanofi Company." https://clinicaltrials.gov/study/NCT06736041

### Jun to Sep 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Pneumococcal Immunization; Healthy Volunteers.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07348692 (Lot-to-lot Consistency Study of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From 2 Months of Age): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-06-07 (ESTIMATED); Lead Sponsor Sanofi." https://clinicaltrials.gov/study/NCT07348692

### June 2027: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Pneumococcal Immunization; Healthy Volunteers.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07348692 (Lot-to-lot Consistency Study of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From 2 Months of Age): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-06-07 (ESTIMATED); Lead Sponsor Sanofi." https://clinicaltrials.gov/study/NCT07348692

### Aug to Nov 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Pneumococcal Immunization; Healthy Volunteers.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06975878 (Study of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-08-25 (ESTIMATED); Lead Sponsor Sanofi." https://clinicaltrials.gov/study/NCT06975878

### August 2027: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Pneumococcal Immunization; Healthy Volunteers.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06975878 (Study of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-08-25 (ESTIMATED); Lead Sponsor Sanofi." https://clinicaltrials.gov/study/NCT06975878

### Sep to Dec 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Pneumococcal Immunization.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06824181 (Study of Mixed Vaccination Schedules With a 21-valent Pneumococcal Conjugate Vaccine and a 20-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-09-10 (ESTIMATED); Lead Sponsor Sanofi." https://clinicaltrials.gov/study/NCT06824181

### September 2027: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Pneumococcal Immunization.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06824181 (Study of Mixed Vaccination Schedules With a 21-valent Pneumococcal Conjugate Vaccine and a 20-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-09-10 (ESTIMATED); Lead Sponsor Sanofi." https://clinicaltrials.gov/study/NCT06824181

### Oct 2027 to Jan 2028: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Pneumococcal Immunization.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06824194 (Study of the Safety of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-10-22 (ESTIMATED); Lead Sponsor Sanofi." https://clinicaltrials.gov/study/NCT06824194

### October 2027: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Pneumococcal Immunization.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06824194 (Study of the Safety of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-10-22 (ESTIMATED); Lead Sponsor Sanofi." https://clinicaltrials.gov/study/NCT06824194

Calendar months: [May 2027](https://sec-api.dev/fda-calendar/2027-05), [June 2027](https://sec-api.dev/fda-calendar/2027-06), [August 2027](https://sec-api.dev/fda-calendar/2027-08), [September 2027](https://sec-api.dev/fda-calendar/2027-09), [October 2027](https://sec-api.dev/fda-calendar/2027-10)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/pcv21-vaccine.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Pcv21 vaccine PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/pcv21-vaccine

```bibtex
@misc{secapidev_pdufa_pcv21_vaccine_20261116,
  title        = {Pcv21 vaccine PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/pcv21-vaccine}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_pcv21_vaccine_20261116","title":"Pcv21 vaccine PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/pcv21-vaccine","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
